Analyst Price Targets — COGT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 1:55 pm | — | Robert W. Baird | $35.00 | $38.29 | TheFly | Cogent Biosciences price target raised to $35 from $34 at Baird |
| February 18, 2026 11:43 am | — | Piper Sandler | $52.00 | $37.62 | TheFly | Cogent Biosciences price target raised to $52 from $39 at Piper Sandler |
| January 7, 2026 5:41 am | Michael Yee | UBS | $60.00 | $34.78 | StreetInsider | UBS Starts Cogent (COGT) at Buy |
| January 6, 2026 11:09 am | — | H.C. Wainwright | $52.00 | $34.26 | TheFly | Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright |
| December 8, 2025 4:03 pm | — | Jefferies | $48.00 | $39.97 | TheFly | Cogent Biosciences price target raised to $48 from $45 at Jefferies |
| November 11, 2025 9:27 am | Chris Raymond | Raymond James | $60.00 | $32.46 | StreetInsider | Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite' |
| November 10, 2025 4:01 pm | — | Stifel Nicolaus | $40.00 | $34.97 | TheFly | Cogent upgraded to Buy at Stifel after 'overwhelmingly positive' GIST data |
| November 10, 2025 3:19 pm | David Nierengarten | Wedbush | $38.00 | $34.76 | TheFly | Wedbush upgrades Cogent to Outperform after better-than-expected trial results |
| October 15, 2025 8:13 pm | — | Stifel Nicolaus | $16.00 | $16.58 | TheFly | Cogent Biosciences initiated with a Hold at Stifel |
| September 2, 2025 8:31 pm | — | Raymond James | $30.00 | $12.00 | TheFly | Cogent Biosciences initiated with a Strong Buy at Raymond James |
Latest News for COGT
– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors
Cogent Biosciences, Inc. maintains a Buy rating as bezuclastinib demonstrates blockbuster potential in GIST and systemic mastocytosis (SM) indications. Bezuclastinib nearly doubled median PFS in 2L GIST (PEAK trial), supporting a high peak market share assumption despite competitive pressures. COGT's sum-of-the-parts valuation yields a fair value of $26.54/share, with current cash reserves likely sufficient to reach…
Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Analyst Ratings This is a breakdown of recent
WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) who…
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for COGT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.